삼성서울병원

Ko En
의료진 검색
찾으실 의료진명을 입력하여 검색해주세요.

혈액종양내과 임호영 교수

진료분야
대장암, 간암
진료일정 04 月
날짜
월
01
화
02
수
03
목
04
금
05
토
06
일
07
월
08
화
09
수
10
목
11
금
12
토
13
일
14
월
15
화
16
수
17
목
18
금
19
토
20
일
21
월
22
화
23
수
24
목
25
금
26
토
27
일
28
월
29
화
30
오전
오후
진료일정 05 月
날짜
수
01
목
02
금
03
토
04
일
05
월
06
화
07
수
08
목
09
금
10
토
11
일
12
월
13
화
14
수
15
목
16
금
17
토
18
일
19
월
20
화
21
수
22
목
23
금
24
토
25
일
26
월
27
화
28
수
29
목
30
금
31
오전
오후
본원외래 본원클리닉 본원육아상담 암병원외래 암병원클리닉 암병원육아상담

학력

학력
2001.08 고려대학교 대학원 의학과 의학박사
1995.02 연세대학교 대학원 의학과 의학석사
1984.02 연세대학교 의과대학 의학과 의학사

경력

경력
2006.03 ~현재 삼성서울병원 혈액종양내과 교수
1993.04 ~ 2006.02 아주대학교 의과대학 종양혈액내과 교수
1995.11 ~ 1997.10 미국 Johns Hopkins Hospital Oncology Center Fellow
1991.05 ~ 1993.03 연세대학교 의과대학 혈액종양내과 연구강사
1984.03 ~ 1988.02 연세대학교 신촌세브란스병원 내과 전공의

학회활동

학회활동
대한 내과학회 정회원
대한 암학회 정회원
대한 종양내과학회 정회원
미국 암연구학회 정회원
미국 암학회 정회원
유럽 간학회 정회원
유럽 암학회 정회원
논문
  • NAT MED 2024 10.1038/s41591-024-02824-y Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial Kim, HD; Jung, S; Lim, HY; Ryoo, BY; Ryu, MH; Chuah, S; Chon, HJ; Kang, B; Hong, JY; Lee, HC; Moon, DB; Kim, KH; Kim, TW; Tai, D; Chew, V; Lee, JS; Finn, RS; Koh, JY; Yoo, C
    View PubMed
  • TARGET ONCOL 2024 10.1007/s11523-023-01029-6 Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma Camera, S; Rimini, M; Rossari, F; Tada, T; Suda, G; Shimose, S; Kudo, M; Yoo, C; Cheon, J; Finkelmeier, F; Lim, HY; Presa, J; Masi, G; Bergamo, F; Salani, F; Marseglia, M; Amadeo, E; Vitiello, F; Kumada, T; Sakamoto, N; Iwamoto, H; Aoki, T; Chon, HJ; Himmelsbach, V; Iavarone, M; Cabibbo, G; Montes, M; Foschi, FG; Vivaldi, C; Lonardi, S; Sho, T; Niizeki, T; Nishida, N; Steup, C; Hirooka, M; Kariyama, K; Tani, J; Atsukawa, M; Takaguchi, K; Itobayashi, E; Fukunishi, S; Tsuji, K; Ishikawa, T; Tajiri, K; Ochi, H; Yasuda, S; Toyoda, H; Ogawa, C; Nishimura, T; Hatanaka, T; Kakizaki, S; Shimada, N; Kawata, K; Hiraoka, A; Tada, F; Ohama, H; Nouso, K; Morishita, A; Tsutsui, A; Nagano, T; Itokawa, N; Okubo, T; Imai, M; Kosaka, H; Naganuma, A; Koizumi, Y; Nakamura, S; Kaibori, M; Iijima, H; Hiasa, Y; Persano, M; Foti, S; Piscaglia, F; Scartozzi, M; Cascinu, S; Casadei-Gardini, A
    View PubMed
  • LANCET ONCOL 2023 Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002) a randomised, double-blind, phase 3 trial Llovet, JM; Kudo, M; Merle, P; Meyer, T; Qin, SK; Ikeda, M; Xu, RC; Edeline, J; Ryoo, BY; Ren, ZG; Masi, G; Kwiatkowski, M; Lim, HY; Kim, JH; Breder, V; Kumada, H; Cheng, AL; Galle, PR; Kaneko, S; Wang, AR; Mody, K; Dutcus, C; Dubrovsky, L; Siegel, AB; Finn, RS
    View PubMed
  • J GASTROINTEST ONCOL 2023 10.21037/jgo-23-418 Effect of ramucirumab plus paclitaxel in advanced gastric cancer according to the status of programmed cell death-ligand 1 (PD-L1) expression Choi, DH; Lee, J; Lim, HY; Kang, WK; Jang, JY; Jeon, Y; Jeong, SY; Jung, YJ; Kim, ST
    View PubMed
  • SCI ADV 2023 10.1126/sciadv.adk1098 Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer Hyung, S; Ko, J; Heo, YJ; Blum, SM; Kim, ST; Park, SH; Park, JO; Kang, WK; Lim, HY; Klempner, SJ; Lee, J
    View PubMed
  • INT J CANCER 2023 10.1002/ijc.34799 α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma Rossari, F; Tada, T; Suda, G; Shimose, S; Kudo, M; Yoo, C; Cheon, J; Finkelmeier, F; Lim, HY; Presa, J; Masi, G; Bergamo, F; Amadeo, E; Vitiello, F; Kumada, T; Sakamoto, N; Iwamoto, H; Aoki, T; Chon, HJ; Himmelsbach, V; Iavarone, M; Cabibbo, G; Montes, M; Foschi, FG; Vivaldi, C; Soldà, C; Sho, T; Niizeki, T; Nishida, N; Steup, C; Hirooka, M; Kariyama, K; Tani, J; Atsukawa, M; Takaguchi, K; Itobayashi, E; Fukunishi, S; Tsuji, K; Ishikawa, T; Tajiri, K; Ochi, H; Yasuda, S; Toyoda, H; Ogawa, C; Nishimura, T; Hatanaka, T; Kakizaki, S; Shimada, N; Kawata, K; Hiraoka, A; Tada, F; Ohama, H; Nouso, K; Morishita, A; Tsutsui, A; Nagano, T; Itokawa, N; Okubo, T; Imai, M; Kosaka, H; Naganuma, A; Koizumi, Y; Nakamura, S; Kaibori, M; Iijima, H; Hiasa, Y; Persano, M; Burgio, V; Piscaglia, F; Scartozzi, M; Cascinu, S; Casadei-Gardini, A; Rimini, M
    View PubMed
  • J GASTROINTEST ONCOL 2023 10.21037/jgo-23-375 Effect of human epidermal growth factor receptor 2 overexpression in metastatic colorectal cancer on standard chemotherapy outcomes Jang, JY; Jeon, YK; Jeong, SY; Lim, SH; Park, YS; Lim, HY; Lee, JY; Kim, ST
    View PubMed
  • ONCOL RES 2023 10.32604/or.2023.030374 Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer Lim, SH; Cho, HJ; Kim, KM; Lim, HY; Kang, WK; Lee, J; Park, YS; Kim, HC; Kim, ST
    View PubMed
  • J CLIN ONCOL 2023 10.1200/JCO.22.01740 Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study Park, JH; Hong, JY; Shen, JJ; Han, K; Park, JO; Park, YS; Lim, HY
    View PubMed
  • GUT LIVER 2023 10.5009/gnl220406 Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea Han, S; Kim, DY; Lim, HY; Yoon, JH; Ryoo, BY; Kim, Y; Kim, K; Kim, BY; Yi, SY; Kim, DS; Cho, DY; Yu, J; Kim, S; Park, JW
    View PubMed
  • EUR J CANCER 2023 10.1016/j.ejca.2023.05.021 Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients Persano, M; Rimini, M; Tada, T; Suda, G; Shimose, S; Kudo, M; Cheon, J; Finkelmeier, F; Lim, HY; Presa, J; Masi, G; Yoo, C; Lonardi, S; Tovoli, F; Kumada, T; Sakamoto, N; Iwamoto, H; Aoki, T; Chon, HJ; Himmelsbach, V; Niizeki, T; Montes, M; Vivaldi, C; Solda, C; Stefanini, B; Hiraoka, A; Sho, T; Nishida, N; Steup, C; Iavarone, M; Di Costanzo, G; Marra, F; Tamburini, E; Cabibbo, G; Foschi, FG; Silletta, M; Hirooka, M; Kariyama, K; Tani, J; Atsukawa, M; Takaguchi, K; Itobayashi, E; Fukunishi, S; Tsuji, K; Ishikawa, T; Tajiri, K; Ochi, H; Yasuda, S; Toyoda, H; Ogawa, C; Nishimura, T; Hatanaka, T; Kakizaki, S; Shimada, N; Kawata, K; Tada, F; Ohama, H; Nouso, K; Morishita, A; Tsutsui, A; Nagano, T; Itokawa, N; Okubo, T; Arai, T; Imai, M; Kosaka, H; Naganuma, A; Koizumi, Y; Nakamura, S; Kaibori, M; Iijima, H; Hiasa, Y; Campani, C; Amadeo, E; Rossari, F; Burgio, V; Cascinu, S; Scartozzi, M; Casadei-Gardini, A
    View PubMed
  • THER ADV GASTROENTER 2023 10.1177/17562848231170484 The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation Jeong, SY; Hong, JY; Park, JO; Park, YS; Lim, HY; Jang, JY; Jeon, Y; Kim, ST
    View PubMed
  • LIVER CANCER 2023 10.1159/000531182 Thyroid Dysfunction After Atezolizumab and Bevacizumab is Associated with Favorable Outcomes in Hepatocellular Carcinoma Song, YS; Yang, HN; Kang, BD; Cheon, J; Kim, I; Kim, H; Lee, WS; Sang, YB; Jung, SH; Lim, HY; Gaillard, VE; Kim, C; Chon, HJ
    View PubMed
  • ANTICANCER RES 2023 10.21873/anticanres.16310 Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index Persano, M; Rimini, M; Tada, T; Suda, G; Shimose, S; Kudo, M; Cheon, J; Finkelmeier, F; Lim, HY; Presa, J; Masi, G; Yoo, C; Lonardi, S; Pressiani, T; Piscaglia, F; Kumada, T; Rimassa, L; Scartozzi, M; Cascinu, S; Casadei-Gardini, A
    View PubMed
  • TARGET ONCOL 2023 10.1007/s11523-023-00953-x Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? Rimini, M; Persano, M; Tada, T; Suda, G; Shimose, S; Kudo, M; Cheon, J; Finkelmeier, F; Lim, HY; Presa, J; Masi, G; Yoo, C; Lonardi, S; Piscaglia, F; Kumada, T; Sakamoto, N; Iwamoto, H; Aoki, T; Chon, HJ; Himmelsbach, V; Pressiani, T; Montes, M; Vivaldi, C; Solda, C; Hiraoka, A; Sho, T; Niizeki, T; Nishida, N; Steup, C; Hirooka, M; Kariyama, K; Tani, J; Atsukawa, M; Takaguchi, K; Itobayashi, E; Fukunishi, S; Tsuji, K; Ishikawa, T; Tajiri, K; Ochi, H; Yasuda, S; Toyoda, H; Ogawa, C; Nishimura, T; Hatanaka, T; Kakizaki, S; Shimada, N; Kawata, K; Tada, F; Ohama, H; Nouso, K; Morishita, A; Tsutsui, A; Nagano, T; Itokawa, N; Okubo, T; Arai, T; Imai, M; Kosaka, H; Naganuma, A; Koizumi, Y; Nakamura, S; Kaibori, M; Iijima, H; Hiasa, Y; Burgio, V; Rimassa, L; Scartozzi, M; Cascinu, S; Casadei-Gardini, A
    View PubMed
  • LIVER CANCER 2023 10.1159/000529636 Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial Merle, P; Kudo, M; Edeline, J; Bouattour, M; Cheng, AL; Chan, SL; Yau, T; Garrido, M; Knox, J; Daniele, B; Breder, V; Lim, HY; Ogasawara, S; Cattan, S; Chao, Y; Siegel, AB; Martinez-Forero, I; Wei, ZW; Liu, CC; Finn, RS
    View PubMed
  • EUR J CANCER 2023 10.1016/j.ejca.2022.11.017 Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population Casadei-Gardini, A; Rimini, M; Tada, T; Suda, G; Shimose, S; Kudo, M; Cheon, J; Finkelmeier, F; Lim, HY; Rimassa, L; Presa, J; Masi, G; Yoo, C; Lonardi, S; Tovoli, F; Kumada, T; Sakamoto, N; Iwamoto, H; Aoki, T; Chon, HJ; Himmelsbach, V; Pressiani, T; Montes, M; Vivaldi, C; Solda, C; Piscaglia, F; Hiraoka, A; Sho, T; Niizeki, T; Nishida, N; Steup, C; Iavarone, M; Di Costanzo, G; Marra, F; Scartozzi, M; Tamburini, E; Cabibbo, G; Foschi, FG; Silletta, M; Hirooka, M; Kariyama, K; Tani, J; Atsukawa, M; Takaguchi, K; Itobayashi, E; Fukunishi, S; Tsuji, K; Ishikawa, T; Tajiri, K; Ochi, H; Yasuda, S; Toyoda, H; Ogawa, C; Nishimura, T; Hatanaka, T; Kakizaki, S; Shimada, N; Kawata, K; Tada, F; Ohama, H; Nouso, K; Morishita, A; Tsutsui, A; Nagano, T; Itokawa, N; Okubo, T; Arai, T; Imai, M; Kosaka, H; Naganuma, A; Koizumi, Y; Nakamura, S; Kaibori, M; Iijima, H; Hiasa, Y; Burgio, V; Persano, M; Della Corte, A; Ratti, F; De Cobelli, F; Aldrighetti, L; Cascinu, S; Cucchetti, A
    View PubMed
  • ONCOLOGY-BASEL 2023 10.1159/000528818 Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab Mara, P; Rimini, M; Tada, T; Suda, G; Shimose, S; Kudo, M; Cheon, J; Finkelmeier, F; Lim, HY; Ramos, JP; Masi, G; Yoo, C; Lonardi, S; Stefanini, B; Kumada, T; Sakamoto, N; Iwamoto, H; Aoki, T; Chon, HJ; Himmelsbach, V; Montes, M; Vivaldi, C; Solda, C; Hiraoka, A; Sho, T; Niizeki, T; Nishida, N; Steup, C; Hirooka, M; Kariyama, K; Tani, J; Atsukawa, M; Takaguchi, K; Itobayashi, E; Fukunishi, S; Tsuji, K; Ishikawa, T; Tajiri, K; Ochi, H; Yasuda, S; Toyoda, H; Ogawa, C; Nishimura, T; Hatanaka, T; Kakizaki, S; Shimada, N; Kawata, K; Tada, F; Ohama, H; Nouso, K; Morishita, A; Tsutsui, A; Nagano, T; Itokawa, N; Okubo, T; Arai, T; Imai, M; Kosaka, H; Naganuma, A; Koizumi, Y; Nakamura, S; Kaibori, M; Iijima, H; Hiasa, Y; Burgio, V; Della Corte, A; Ratti, F; De Cobelli, F; Aldrighetti, L; Scartozzi, M; Cascinu, S; Casadei-Gardini, A
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2021.1527 A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer Jo, H; Kim, ST; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Il Yu, J; Park, HC; Choi, DH; Park, Y; Cho, YB; Huh, JW; Yun, SH; Kim, HC; Lee, WY; Kang, WK
    View PubMed
  • J CANCER RES CLIN 2022 10.1007/s00432-022-04512-1 Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study Persano, M; Rimini, M; Tada, T; Suda, G; Shimose, S; Kudo, M; Cheon, J; Finkelmeier, F; Lim, HY; Rimassa, L; Presa, J; Masi, G; Yoo, C; Lonardi, S; Tovoli, F; Kumada, T; Sakamoto, N; Iwamoto, H; Aoki, T; Chon, HJ; Himmelsbach, V; Pressiani, T; Kawaguchi, T; Montes, M; Vivaldi, C; Solda, C; Piscaglia, F; Hiraoka, A; Sho, T; Niizeki, T; Nishida, N; Steup, C; Iavarone, M; Di Costanzo, G; Marra, F; Scartozzi, M; Tamburini, E; Cabibbo, G; Foschi, FG; Silletta, M; Hirooka, M; Kariyama, K; Tani, J; Atsukawa, M; Takaguchi, K; Itobayashi, E; Fukunishi, S; Tsuji, K; Ishikawa, T; Tajiri, K; Ochi, H; Yasuda, S; Toyoda, H; Ogawa, C; Nishimura, T; Hatanaka, T; Kakizaki, S; Shimada, N; Kawata, K; Tada, F; Ohama, H; Nouso, K; Morishita, A; Tsutsui, A; Nagano, T; Itokawa, N; Okubo, T; Arai, T; Imai, M; Kosaka, H; Naganuma, A; Koizumi, Y; Nakamura, S; Kaibori, M; Iijima, H; Hiasa, Y; Cammarota, A; Burgio, V; Cascinu, S; Casadei-Gardini, A
    View PubMed
  • PATHOL ONCOL RES 2022 10.3389/pore.2022.1610697 MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer Ko, J; Jung, J; Kim, ST; Hong, JY; Park, S; Park, JO; Park, YS; Lim, HY; Ahn, S; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • JAMA ONCOL 2022 10.1001/jamaoncol.2022.4733 Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma Kim, C; Yang, H; Kim, I; Kang, B; Kim, H; Kim, H; Lee, WS; Jung, S; Lim, HY; Cheon, J; Chon, HJ
    View PubMed
  • CLIN ONCOL-UK 2022 10.1016/j.clon.2022.02.011 A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer Jo, H; Lee, MS; Lee, YP; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • THER ADV MED ONCOL 2022 10.1177/17588359221113266 The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma Kim, HS; Kim, CG; Hong, JY; Kim, IH; Kang, B; Jung, S; Kim, C; Shin, SJ; Choi, HJ; Cheon, J; Chon, HJ; Lim, HY
    View PubMed
  • FUTURE ONCOL 2022 10.2217/fon-2022-0524 Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib Lim, DH; Casadei-Gardini, A; Lee, MA; Lonardi, S; Kim, JW; Masi, G; Chon, HJ; Rimini, M; Kim, I; Cheon, J; Hwang, JE; Kang, JH; Lim, HY; Yoo, C
    View PubMed
  • J EXP CLIN CANC RES 2022 10.1186/s13046-022-02383-5 A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors Chan, TH; Schuler, M; Kang, YK; Yen, CJ; Edeline, J; Choo, SP; Lin, CC; Okusaka, T; Weiss, KH; Macarulla, T; Cattan, S; Blanc, JF; Lee, KH; Maur, M; Pant, S; Kudo, M; Assenat, E; Zhu, AR; Yau, T; Lim, HY; Bruix, J; Geier, A; Guillen-Ponce, C; Fasolo, A; Finn, RS; Fan, J; Vogel, A; Qin, SK; Riester, M; Katsanou, V; Chaudhari, M; Kakizume, T; Gu, Y; Porta, DG; Myers, A; Delord, JP
    View PubMed
  • FRONT ONCOL 2022 10.3389/fonc.2022.888755 Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis Yu, JI; Kang, W; Yoo, GS; Goh, MJ; Sinn, DH; Gwak, GY; Paik, YH; Choi, MS; Lee, JH; Koh, KC; Paik, SW; Hong, JY; Lim, HY; Park, B; Park, HC
    View PubMed
  • ANN SURG ONCOL 2022 10.1245/s10434-022-11592-3 Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer Yu, JI; Yoo, GS; Park, HC; Choi, DH; Lee, WY; Yun, SH; Kim, HC; Cho, YB; Huh, JW; Park, YA; Shin, JK; Park, JO; Kim, ST; Park, YS; Lee, J; Kang, WK; Lim, HY; Hong, JY
    View PubMed
  • ANN SURG ONCOL 2022 10.1245/s10434-022-11688-w ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer Yu, JI; Yoo, GS; Park, HC; Choi, DH; Lee, WY; Yun, SH; Kim, HC; Cho, YB; Huh, JW; Park, YA; Shin, JK; Park, JO; Kim, ST; Park, YS; Lee, J; Kang, WK; Lim, HY; Hong, JY
    View PubMed
  • J HEPATOL 2022 10.1016/j.jhep.2021.11.030 Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Cheng, AL; Qin, SK; Ikeda, M; Galle, PR; Ducreux, M; Kim, TY; Lim, HY; Kudo, M; Breder, V; Merle, P; Kaseb, AO; Li, DN; Verret, W; Ma, N; Nicholas, A; Wang, YF; Li, LD; Zhu, AX; Finn, RS
    View PubMed
  • J CANCER 2022 10.7150/jca.67050 Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm phase-II trial Kim, R; Ji, JH; Kim, JH; Hong, JY; Lim, HY; Kang, WK; Lee, J; Kim, ST
    View PubMed
  • GENOME MED 2022 10.1186/s13073-021-00995-8 Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial Hong, JY; Cho, HJ; Sa, JK; Liu, XQ; Ha, SY; Lee, T; Kim, H; Kang, W; Sinn, DH; Gwak, GY; Choi, MS; Lee, JH; Koh, KC; Paik, SW; Park, HC; Kang, TW; Rhim, H; Lee, SJ; Cristescu, R; Lee, J; Paik, YH; Lim, HY
    View PubMed
  • FRONT ONCOL 2021 10.3389/fonc.2021.792340 The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers Kim, HR; Ahn, S; Jo, H; Kim, H; Hong, J; Lee, J; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • LIVER CANCER 2021 10.1159/000519867 Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma Rimassa, L; Kelley, RK; Meyer, T; Ryoo, BY; Merle, P; Park, JW; Blanc, JF; Lim, HY; Tran, A; Chan, YW; McAdam, P; Wang, EVY; Cheng, AL; El-Khoueiry, AB; Abou-Alfa, GK
    View PubMed
  • LIVER INT 2021 10.1111/liv.15102 Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma Cheon, J; Yoo, C; Hong, JY; Kim, HS; Lee, DW; Lee, MA; Kim, JW; Kim, I; Oh, SB; Hwang, JE; Chon, HJ; Lim, HY
    View PubMed
  • J CANCER RES CLIN 2021 10.1007/s00432-021-03781-6 The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors Kim, H; Ahn, S; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
    View PubMed
  • J CLIN ONCOL 2021 10.1200/JCO.20.03555 Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study Kelley, RK; Sangro, B; Harris, W; Ikeda, M; Okusaka, T; Kang, YK; Qin, SK; Tai, DWM; Lim, HY; Yau, T; Yong, WP; Cheng, AL; Gasbarrini, A; Damian, S; Bruix, J; Borad, M; Bendell, J; Kim, TY; Standifer, N; He, P; Makowsky, M; Negro, A; Kudo, M; Abou-Alfa, GK
    View PubMed
  • CLIN CANCER RES 2021 10.1158/1078-0432.CCR-21-0251 Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer Kim, ST; Smith, SA; Mortimer, P; Loembe, AB; Cho, H; Kim, KM; Smith, C; Willis, S; Irurzun-Arana, I; Berges, A; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kozarewa, I; Pierce, AJ; Dean, E; Lee, J
    View PubMed
  • CLIN DRUG INVEST 2021 10.1007/s40261-021-01063-0 Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma Ryoo, BY; Palmer, DH; Park, SR; Rimassa, L; Sarker, D; Daniele, B; Steinberg, J; Lopez, B; Lim, HY
    View PubMed
  • CANCER-AM CANCER SOC 2021 10.1002/cncr.33870 Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study Harding, JJ; Yang, TS; Chen, YY; Feng, YH; Yen, CJ; Ho, CL; Huang, WT; El Dika, I; Akce, M; Tan, B; Cohen, SA; Meyer, T; Sarker, D; Lee, DW; Ryoo, BY; Lim, HY; Johnston, A; Bomalaski, JS; O'Reilly, EM; Qin, SK; Abou-Alfa, GK
    View PubMed
  • LIVER CANCER 2021 10.1159/000516605 Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2) Kudo, M; Finn, RS; Morimoto, M; Rau, KM; Ikeda, M; Yen, CJ; Galle, PR; Llovet, JM; Daniele, B; Lim, HY; McIlwain, DW; Yoshikawa, R; Nakamura, K; Liang, K; Wang, CX; Abada, P; Widau, RC; Zhu, AX
    View PubMed
  • J CANCER 2021 10.7150/jca.62853 When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer Kim, H; Kim, H; Lee, M; Kwon, M; Hong, JY; Lee, J; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • BRIT J CANCER 2021 10.1038/s41416-021-01380-3 Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression Ryoo1, BY; Cheng, AL; Ren, ZG; Kim, TY; Pan, HM; Rau, KM; Choi, HJ; Park, JW; Kim, JH; Yen, CJ; Lim, HY; Zhou, DL; Straub, J; Scheele, J; Berghoff, K; Qin, SK
    View PubMed
  • ADV THER 2021 10.1007/s12325-021-01700-2 Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein >= 400 ng/mL: A Matching-Adjusted Indirect Comparison Trojan1, J; Mollon, P; Daniele, B; Marteau, F; Martin, L; Li, YX; Xu, Q; Piscaglia, F; Zaucha, R; Sarker, D; Lim, HY; Venerito, M
    View PubMed
  • LIVER CANCER 2021 10.1159/000515553 Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial Kudo1, M; Lim, HY; Cheng, AL; Chao, Y; Yau, T; Ogasawara, S; Kurosaki, M; Morimoto, N; Ohkawa, K; Yamashita, T; Lee, KH; Chen, ER; Siegel, AB; Ryoo, BY
    View PubMed
  • EUR UROL 2021 10.1016/j.eururo.2020.12.029 Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial Motzer1, RJ; Russo, P; Haas, N; Doehn, C; Donskov, F; Gross-Goupil, M; Varlamov, S; Kopyltsov, E; Lee, JL; Lim, HY; Melichar, B; Zemanova, M; Rini, B; Choueirim, TK; Wood, L; Reaume, MN; Stenzl, A; Chowdhury, S; McDermott, R; Michael, A; Izquierdo, M; Aimone, P; Zhang, H; Sternberg, CN
    View PubMed
  • ONCOLOGY-BASEL 2021 10.1159/000514404 Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer Kim1, H; Kim, J; Byeon, S; Jang, KT; Hong, JY; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • ANN ONCOL 2021 10.1016/j.annonc.2020.11.017 A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial Park1, SH; Lim, DH; Sohn, TS; Lee, J; Zang, DY; Kim, ST; Kang, JH; Oh, SY; Hwang, IG; Ji, JH; Shin, DB; Yu, JI; Kim, KM; An, JY; Choi, MG; Lee, JH; Kim, S; Hong, JY; Park, JO; Park, YS; Lim, HY; Bae, JM; Kang, WK
    View PubMed
  • THER ADV MED ONCOL 2021 10.1177/1758835921992992 Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors Kim1, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
    View PubMed
  • J HEPATOL 2021 10.1016/j.jhep.2020.08.010 Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma Kim1, CG; Kim, C; Yoon, SE; Kim, KH; Choi, SJ; Kang, B; Kim, HR; Park, SH; Shin, EC; Kim, YY; Kim, DJ; Chung, HC; Chon, HJ; Choi, HJ; Lim, HY
    View PubMed
  • J CANCER 2021 10.7150/jca.49176 Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer Kim1, J; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • IN VIVO 2021 10.21873/invivo.12284 ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy Kim1, H; Kim, ST; Yoo, KH; Hong, JY; Park, YS; Lim, HY; Park, JO
    View PubMed
  • JAMA ONCOL 2020 10.1001/jamaoncol.2020.4564 Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial Yau1, T; Kang, YK; Kim, TY; El-Khoueiry, AB; Santoro, A; Sangro, B; Melero, I; Kudo, M; Hou, MM; Matilla, A; Tovoli, F; Knox, JJ; He, AR; El-Rayes, BF; Acosta-Rivera, M; Lim, HY; Neely, J; Shen, Y; Wisniewski, T; Anderson, J; Hsu, C
    View PubMed
  • CANCER 2020 10.1002/cncr.33317 Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma KEYNOTE-240 Ryoo1, BY; Merle, P; Kulkarni, AS; Cheng, AL; Bouattour, M; Lim, HY; Breder, V; Edeline, J; Chao, Y; Ogasawara, S; Yau, T; Garrido, M; Chan, SL; Daniele, B; Norquist, JM; Chen, E; Siegel, AB; Zhu, AX; Finn, RS; Kudo, M
    View PubMed
  • THER ADV MED ONCOL 2020 10.1177/1758835920965842 Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment Lee1, MS; Cho, HJ; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Cho, YB; Kim, ST
    View PubMed
  • CANCERS 2020 10.3390/cancers12092395 Do Biliary Complications after Proton Beam Therapy for Perihilar Hepatocellular Carcinoma Matter? Yoo1, GS; Il Yu, J; Park, HC; Hyun, D; Jeong, WK; Lim, HY; Choi, MS; Ha, SY
    View PubMed
  • EXPERT OPIN INV DRUG 2020 10.1080/13543784.2020.1804855 Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors Kim1, S; Kim, S; Park, YS; Park, JO; Lim, HY; Ahn, JS; Lee, J; Sun, JM; Kang, WK; Han, R; Kim, J; Ahn, MJ
    View PubMed
  • LIVER CANCER 2020 10.1159/000506946 Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein Pooled Individual Data Analysis of Two Randomized Studies Yen1, CJ; Kudo, M; Lim, HY; Hsu, CH; Vogel, A; Brandi, G; Cheng, R; Nitu, IS; Abada, P; Hsu, YZ; Zhu, AX; Kang, YK
    View PubMed
  • ESMO OPEN 2020 10.1136/esmoopen-2020-000714 Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma a subgroup analysis of the phase 3 CELESTIAL trial Kelley1, RK; Ryoo, BY; Merle, P; Park, JW; Bolondi, L; Chan, SL; Lim, HY; Baron, AD; Parnis, F; Knox, J; Cattan, S; Yau, T; Lougheed, JC; Milwee, S; El-Khoueiry, AB; Cheng, AL; Meyer, T; Abou-Alfa, GK
    View PubMed
  • THER ADV MED ONCOL 2020 10.1177/1758835920926796 First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients Kim1, ST; Hong, JY; Park, SH; Park, JO; Park, YW; Park, N; Lee, H; Hong, SH; Lee, SJ; Song, SW; Kim, K; Park, YS; Lim, HY; Kang, WK; Nam, H; Lee, JW; Park, K; Kim, KM; Lee, J
    View PubMed
  • LIVER INT 2020 10.1111/liv.14496 Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events Yoo1, C; Byeon, S; Bang, Y; Cheon, J; Kim, JW; Kim, JH; Chon, HJ; Kang, B; Kang, MJ; Kim, I; Hwang, JE; Kang, JH; Lee, MA; Hong, JY; Lim, HY; Ryoo, BY
    View PubMed
  • Transl Cancer Res 2020 10.21037/tcr-19-1876 Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer Hong1, JY; An, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, KM; Kang, WK; Kim, ST
    View PubMed
  • NEW ENGL J MED 2020 10.1056/NEJMoa1915745 Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Finn1, RS; Qin, SK; Ikeda, M; Galle, PR; Ducreux, M; Kim, TY; Kudo, M; Breder, V; Merle, P; Kaseb, AO; Li, DN; Verret, W; Xu, DZ; Hernandez, S; Liu, J; Huang, C; Mulla, S; Wang, YL; Lim, HY; Zhu, AX; Cheng, AL
    View PubMed
  • TARGET ONCOL 2020 10.1007/s11523-020-00706-0 Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study Byeon1, S; Hong, JY; Lee, J; Nam, DH; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • BRIT J CANCER 2020 10.1038/s41416-020-0802-1 Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours Hong1, DVS; Kang, YK; Borad, M; Sachdev, J; Ejadi, S; Lim, HY; Brenner, AJ; Park, K; Lee, JL; Kim, TY; Shin, S; Becerra, CR; Falchook, G; Stoudemire, J; Martin, D; Kelnar, K; Peltier, H; Bonato, V; Bader, AG; Smith, S; Kim, S; O'Neill, V; Beg, MS
    View PubMed
  • TARGET ONCOL 2020 10.1007/s11523-020-00713-1 Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients Kim1, J; Byeon, S; Kim, H; Yeo, JH; Hong, JY; Lee, J; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • CANCER RES TREAT 2020 10.4143/crt.2019.261 Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer Yoo1, GS; Park, HC; Yu, JI; Choi, DH; Cho, WK; Park, YS; Park, JO; Lim, HY; Kang, WK; Lee, WY; Kim, HC; Yun, SH; Cho, YB; Park, YA; Song, KD; Kim, SH; Ha, SY
    View PubMed
  • ANN ONCOL 2020 10.1016/j.annonc.2019.12.001 Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO Chen1, LT; Martinelli, E; Cheng, AL; Pentheroudakis, G; Qin, S; Bhattacharyya, GS; Ikeda, M; Lim, HY; Ho, GF; Choo, SP; Ren, Z; Malhotra, H; Ueno, M; Ryoo, BY; Kiang, TC; Tai, D; Vogel, A; Cervantes, A; Lu, SN; Yen, CJ; Huang, YH; Chen, SC; Hsu, C; Shen, YC; Tabernero, J; Yen, Y; Hsu, CH; Yoshino, T; Douillard, JY
    View PubMed
  • EUR J CANCER 2020 10.1016/j.ejca.2019.08.034 Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16) Park1, I; Kim, BS; Lim, HY; Kim, HJ; Lee, HJ; Choi, YJ; Park, KH; Lee, KH; Yoon, S; Hong, B; Hong, JH; Ahn, H; Lee, JL
    View PubMed
  • PATHOL RES PRACT 2020 10.1016/j.prp.2020.152820 TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer Hong1, JY; Kim, HJ; Kim, K; Hong, J; Kim, JE; Byeon, SJ; Lee, IK; Kim, KM; Shim, M; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, J; Kang, WK
    View PubMed
  • TARGET ONCOL 2020 10.1007/s11523-019-00691-z Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study Kim1, ST; Hong, JY; Lee, JY; Park, JO; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • Genome Med 2020 10.1186/s13073-020-0717-8 Comprehensive pharmacogenomic characterization of gastric cancer Sa1, JK; Hong, JY; Lee, IK; Kim, JS; Sim, MH; Kim, HJ; An, JY; Sohn, TS; Lee, JH; Bae, JM; Kim, S; Kim, KM; Kim, ST; Park, SH; Park, JO; Lim, HY; Kang, WK; Her, NG; Lee, Y; Cho, HJ; Shin, YJ; Kim, M; Koo, H; Kim, M; Seo, YJ; Kim, JY; Choi, MG; Nam, DH; Lee, J
    View PubMed
  • J CLIN ONCOL 2020 10.1200/JCO.19.01307 Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial Finn1, RS; Ryoo, BY; Merle, P; Kudo, M; Bouattour, M; Lim, HY; Breder, V; Edeline, J; Chao, Y; Ogasawara, S; Yau, T; Garrido, M; Chan, SL; Knox, J; Daniele, B; Ebbinghaus, SW; Chen, E; Siegel, AB; Zhu, AX; Cheng, AL
    View PubMed
  • J ONCOL 2020 10.1155/2020/4659062 Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers Lee1, SJ; Hong, JY; Kim, K; Kim, KM; Kang, SY; Lee, T; Kim, ST; Park, SH; Park, YS; Lim, HY; Kang, WK; Lee, J; Park, JO
    View PubMed
  • CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0555 First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma Kim1, RD; Sarker, D; Meyer, T; Yau, T; Macarulla, T; Park, JW; Choo, SP; Hollebecque, A; Sung, MW; Lim, HY; Mazzaferro, V; Trojan, J; Zhu, AX; Yoon, JH; Sharma, S; Lin, ZZ; Chan, SL; Faivre, S; Feun, LG; Yen, CJ; Dufour, JF; Palmer, DH; Llovet, JM; Manoogian, M; Tugnait, M; Stransky, N; Hagel, M; Kohl, NE; Lengauer, C; Sherwin, CA; Schmidt-Kittler, O; Hoeflich, KP; Shi, HL; Wolf, BB; Kang, YK
    View PubMed
  • Cancer Med 2019 10.1002/cam4.2570 Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma Yu1, JI; Lee, SJ; Lee, J; Lim, HY; Paik, SW; Yoo, GS; Choi, C; Park, HC
    View PubMed
  • Front Oncol 2019 10.3389/fonc.2019.01327 Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening Lim1, SH; Sa, JK; Lee, DW; Kim, J; Kim, ST; Park, SH; Ku, B; Park, JO; Park, YS; Lim, H; Kang, WK; Nam, DH; Lee, J
    View PubMed
  • SCI REP-UK 2019 10.1038/s41598-019-51981-5 Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients Bray1, SM; Lee, J; Kim, ST; Hur, JY; Ebert, PJ; Calley, JN; Wulur, IH; Gopalappa, T; Wong, SS; Qian, HR; Ting, JC; Liu, JG; Willard, MD; Novosiadly, RD; Park, YS; Park, JO; Lim, HY; Kang, WK; Aggarwal, A; Kim, HC; Reinhard, C
    View PubMed
  • J Cancer 2019 10.7150/jca.37610 Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial Kim1, ST; Oh, SY; Lee, J; Kang, JH; Lee, HW; Lee, MA; Sohn, BS; Hong, JH; Park, YS; Park, JO; Lim, HY
    View PubMed
  • CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0442 Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial Lee1, J; Kim, ST; Kim, K; Lee, H; Kozarewa, I; Mortimer, PGS; Odegaard, JI; Harrington, EA; Lee, J; Lee, T; Oh, SY; Kang, JH; Kim, JH; Kim, Y; Ji, JH; Kim, YS; Lee, KE; Kim, J; Sohn, TS; An, JY; Choi, MG; Lee, JH; Bae, JM; Kim, S; Kim, JJ; Min, YW; Min, BH; Kim, NKD; Luke, S; Kim, YH; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Talasaz, A; Hollingsworth, SJ; Kim, KM; Kang, WK
    View PubMed
  • J IMMUNOTHER 2019 10.1097/CJI.0000000000000283 LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target Lee1, SJ; Byeon, SJ; Lee, J; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Kim, KM; Kim, ST
    View PubMed
  • ANTICANCER RES 2019 10.21873/anticanres.13785 Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (<= 45 Years) With Gastric Cancer Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Lim, HY; Kim, ST; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S
    View PubMed
  • Transl Cancer Res 2019 10.21037/tcr.2019.09.27 Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs Cho1, JH; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.401 Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols Yu1, JI; Lim, D; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Rae, JM; Yoo, H; Kim, K
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.379 A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients Kim1, Y; Kim, TW; Han, SW; Ahn, JB; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK
    View PubMed
  • Am J Transl Res 2019 Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification Kim1, ST; Lee, IK; Rom, E; Sirkis, R; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Yayon, A; Lee, J
    View PubMed
  • ONCOLOGIST 2019 10.1634/theoncologist.2018-0838 An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma El Dika1, I; Lim, HY; Yong, WP; Lin, CC; Yoon, JH; Modiano, M; Freilich, B; Choi, HJ; Chao, TY; Kelley, RK; Brown, J; Knox, J; Ryoo, BY; Yau, T; Abou-Alfa, GK
    View PubMed
  • INVEST NEW DRUG 2019 10.1007/s10637-018-0707-5 Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma Yoo1, C; Park, JW; Kim, YJ; Kim, DY; Yu, SJ; Lim, TS; Lee, SJ; Ryoo, BY; Lim, HY
    View PubMed
  • J Cancer 2019 10.7150/jca.30355 The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma Yoon1, SE; Kim, JH; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • ANN ONCOL 2019 10.1093/annonc/mdz058 Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial Kim1, ST; Kang, JH; Lee, J; Lee, HW; Oh, SY; Jang, JS; Lee, MA; Sohn, BS; Yoon, SY; Choi, HJ; Hong, JH; Kim, MJ; Kim, S; Park, YS; Park, JO; Lim, HY
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.226 Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma Yoo1, C; Kang, J; Lim, HY; Kim, JH; Lee, MA; Lee, KH; Kim, TY; Ryoo, BY
    View PubMed
  • TRANSL ONCOL 2019 10.1016/j.tranon.2018.12.009 Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial Kim1, ST; Lee, S; Park, M; Park, SH; Park, JO; Lim, HY; Park, YS; Kang, WK; Gangolli, EA; Shin, H; Kim, KM; Hollingsworth, SJ; Mortimer, PGS; Lee, J
    View PubMed
  • CANCER CHEMOTH PHARM 2019 10.1007/s00280-018-3753-y Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer Oh1, SY; Lee, S; Huh, SJ; Lee, J; Kim, ST; Park, SH; Lim, HY; Kang, WK; Kang, BW; Kim, JG; Lee, HJ; Kim, JH; Kang, JH; Kim, H
    View PubMed
  • J Cancer 2019 10.7150/jca.29106 The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • LANCET ONCOL 2019 10.1016/S1470-2045(18)30937-9 Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial Zhu1, AX; Kang, YK; Yen, CJ; Finn, RS; Galle, PR; Llovet, JM; Assenat, E; Brandi, G; Pracht, M; Lim, HY; Rau, KM; Motomura, K; Ohno, I; Merle, P; Daniele, B; Shin, DB; Gerken, G; Borg, C; Hiriart, JB; Okusaka, T; Morimoto, M; Hsu, YZ; Abada, PB; Kudo, M
    View PubMed
  • OncoTargets and therapy 2019 10.2147/OTT.S187621 The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • PLoS One 2019 10.1371/journal.pone.0210730 Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients Sinn1, DH; Choi, GS; Park, HC; Kim, JM; Kim, H; Song, KD; Kang, TW; Lee, MW; Rhim, H; Hyun, D; Cho, SK; Shin, SW; Jeong, WK; Kim, SH; Il Yu, J; Ha, SY; Lee, SJ; Lim, HY; Kim, K; Ahn, JH; Kang, W; Gwak, GY; Paik, YH; Choi, MS; Lee, JH; Koh, KC; Joh, JW; Lim, HK; Paik, SW
    View PubMed
  • INVEST NEW DRUG 2018 10.1007/s10637-018-0658-x Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients Tak1, WY; Ryoo, BY; Lim, HY; Kim, DY; Okusaka, T; Ikeda, M; Hidaka, H; Yeon, JE; Mizukoshi, E; Morimoto, M; Lee, MA; Yasui, K; Kawaguchi, Y; Heo, J; Morita, S; Kim, TY; Furuse, J; Katayama, K; Aramaki, T; Hara, R; Kimura, T; Nakamura, O; Kudo, M
    View PubMed
  • J Gastric Cancer 2018 10.5230/jgc.2018.18.e34 Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial Kim1, Y; Kim, KM; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Lee, SJ; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK; Park, SH
    View PubMed
  • BMC CANCER 2018 10.1186/s12885-018-4995-0 Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line Kim1, ST; Kim, SY; Lee, J; Kim, K; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO
    View PubMed
  • RADIOTHER ONCOL 2018 10.1016/j.radonc.2018.07.002 Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S
    View PubMed
  • CLIN CANCER RES 2018 10.1158/1078-0432.CCR-17-3588 Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma Lim1, HY; Merle, P; Weiss, KH; Yau, T; Ross, P; Mazzaferro, V; Blanc, JF; Ma, YT; Yen, CJ; Kocsis, J; Choo, SP; Sukeepaisarnjaroen, W; Gerolami, R; Dufour, JF; Gane, EJ; Ryoo, BY; Peck-Radosavljevic, M; Dao, T; Yeo, W; Lamlertthon, W; Thongsawat, S; Teufel, M; Roth, K; Reis, D; Childs, BH; Krissel, H; Llovet, JM
    View PubMed
  • NAT MED 2018 10.1038/s41591-018-0101-z Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer Kim1, ST; Cristescu, R; Bass, AJ; Kim, KM; Odegaard, JI; Kim, K; Liu, XQ; Sher, XW; Jung, H; Lee, M; Lee, S; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Choi, M; Talasaz, A; Kang, PS; Cheng, J; Loboda, A; Lee, J; Kang, WK
    View PubMed
  • J Cancer 2018 10.7150/jca.26068 Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation Lee1, T; Kim, K; Lee, J; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO; Kim, ST
    View PubMed
  • CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.02.013 c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival Lee1, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • J Cancer 2018 10.7150/jca.24948 Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial Lim1, SW; Lee, S; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.01.005 Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer Lee1, J; Kim, ST; Park, S; Lee, S; Park, SH; Park, JO; Lim, HY; Ahn, H; Bok, H; Kim, KM; Ahn, MJ; Kang, WK; Park, YS
    View PubMed
  • ANN ONCOL 2018 10.1093/annonc/mdy101 Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma Abou-Alfa1, GK; Qin, S; Ryoo, BY; Lu, SN; Yen, CJ; Feng, YH; Lim, HY; Izzo, F; Colombo, M; Sarker, D; Bolondi, L; Vaccaro, G; Harris, WP; Chen, Z; Hubner, RA; Meyer, T; Sun, W; Harding, JJ; Hollywood, EM; Ma, J; Wan, PJ; Ly, M; Bomalaski, J; Johnston, A; Lin, CC; Chao, Y; Chen, LT
    View PubMed
  • J HEMATOL ONCOL 2018 10.1186/s13045-018-0617-1 Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial Guo1, J; Jin, J; Oya, M; Uemura, H; Takahashi, S; Tatsugami, K; Rha, SY; Lee, JL; Chung, J; Lim, HY; Wu, HC; Chang, YH; Azad, A; Davis, ID; Carrasco-Alfonso, MJ; Nanua, B; Han, J; Ahmad, Q; Motzer, R
    View PubMed
  • TRANSL ONCOL 2018 10.1016/j.tranon.2018.01.007 The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer Lee1, SJ; Kim, JE; Kim, ST; Lee, J; Park, SH; Park, JO; Kang, WK; Park, YS; Lim, HY
    View PubMed
  • CANCER RES TREAT 2018 10.4143/crt.2016.584 Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study Jung1, KS; Lee, SJ; Park, SH; Lee, JL; Lee, SH; Lim, JY; Kang, JH; Lee, S; Rha, SY; Lee, KH; Kim, HY; Lim, HY
    View PubMed
  • J Cancer 2018 10.7150/jca.25132 The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer Kim1, ST; Kim, HK; Lee, J; Park, SH; Lim, HY; Park, YS; Kang, WK; Park, JO
    View PubMed
  • KOREAN JOURNAL OF INTERNAL MEDICINE 2018 10.3904/kjim.2015.162 Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee Kim1, MJ; Kim, YS; Oh, SY; Lee, S; Choi, YJ; Seol, YM; Park, MJ; Kim, KH; Park, LC; Kang, JH; Hwang, IG; Lee, SI; Lim, ST; Kim, HS; Lim, HY; Rha, SY; Kim, HJ
    View PubMed
  • TRANSL ONCOL 2018 10.1016/j.tranon.2017.10.008 Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract Lee1, JY; Kim, K; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Choi, HY; Kwon, GY; Kim, KM; Lee, J; Lim, HY; Park, SH
    View PubMed
  • CANCER RES TREAT 2018 10.4143/crt.2016.535 Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study Choi1, Y; Yun, MS; Lim, SH; Lee, J; Ahn, JH; Kim, YJ; Park, KH; Park, YS; Lim, HY; An, H; Suh, DC; Kim, YH
    View PubMed
  • J CLIN ONCOL 2017 10.1200/JCO.2017.73.5324 Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma Motzer1, RJ; Haas, NB; Donskov, F; Gross-Goupil, M; Varlamov, S; Kopyltsov, E; Lee, JL; Melichar, B; Rini, BI; Choueiri, TK; Zemanova, M; Wood, LA; Reaume, MN; Stenzl, A; Chowdhury, S; Lim, HY; McDermott, R; Michael, A; Bao, WC; Carrasco-Alfonso, MJ; Aimone, P; Voi, M; Doehn, C; Russo, P; Sternberg, CN
    View PubMed
  • INVEST NEW DRUG 2017 10.1007/s10637-017-0463-y Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors Lee1, SJ; Lee, SY; Lee, WS; Yoo, JS; Sun, JM; Lee, J; Park, SH; Park, JO; Ahn, MJ; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.22394 MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines Kim1, JE; Kim, Y; Li, G; Kim, ST; Kim, K; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Sohn, TS; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.22511 Elevated CEA is associated with worse survival in recurrent rectal cancer Cho1, WK; Choi, DH; Park, HC; Park, W; Yu, JI; Park, YS; Park, JO; Lim, HY; Kang, WK; Kim, HC; Cho, YB; Yun, SH; Lee, WY
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.3750 MerTK is a novel therapeutic target in gastric cancer Yi1, JH; Jang, J; Cho, J; Do, IG; Hong, M; Kim, ST; Kim, KM; Lee, S; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Lee, J
    View PubMed
  • ONCOLOGIST 2017 10.1634/theoncologist.2017-0020 Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials Kim1, ST; Kim, KM; Kim, NKD; Park, JO; Ahn, S; Yun, JW; Kim, KT; Park, SH; Park, PJ; Kim, HC; Sohn, TS; Il Choi, D; Cho, JH; Heo, JS; Kwon, W; Lee, H; Min, BH; Hong, SN; Park, YS; Lim, HY; Kang, WK; Park, WY; Lee, J
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.20492 Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy Kim1, ST; Klempner, SJ; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Lee, J
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.18168 The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs Kim1, HK; Ha, SY; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • TRANSL ONCOL 2017 10.1016/j.tranon.2017.03.001 Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model Jang1, J; Kim, HK; Bang, H; Kim, ST; Kim, SY; Park, SH; Lim, HY; Kang, WK; Lee, J; Kim, KM
    View PubMed
  • BMC UROL 2017 10.1186/s12894-017-0253-z A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer Kim1, HS; Lee, JY; Lee, SJ; Lim, HY; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Choi, HY; Park, SH
    View PubMed
  • J Cancer 2017 10.7150/jca.18286 The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer Kim1, ST; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • J Cancer 2017 10.7150/jca.19458 The Impact of Cetuximab Plus AKT- or mTOR-Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation Kim1, JS; Kim, JE; Kim, K; Lee, J; Park, JO; Lim, HY; Park, YS; Kang, WK; Kim, ST
    View PubMed
  • J Cancer 2017 10.7150/jca.19582 MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines Kim1, JE; Kim, KK; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • J Hepatol. 2017 Jun;66(6):1166-1172. doi: 10.1016/j.jhep.2017.01.012. Epub 2017 Jan 26. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC Lencioni R11, Montal R2, Torres F3, Park JW4, Decaens T5, Raoul JL6, Kudo M7, Chang C8, Rios J3, Boige V9, Assenat E10, Kang YK11, Lim HY12, Walters I13, Llovet JM14.
    View PubMed
  • Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition Kim ST11, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.
    View PubMed
  • BMC Cancer. 2017 Mar 23;17(1):211. doi: 10.1186/s12885-017-3196-6. Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy Kim ST11, Lee J1, Park SH1, Park JO1, Park YS1, Kang WK1, Lim HY2.
    View PubMed
  • Asia Pac J Clin Oncol. 2017 Feb;13(1):61-67. doi: 10.1111/ajco.12465. Epub 2016 Mar 31. Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma Lim SH11, Hwang IG2, Ji JH3, Oh SY4, Yi JH5, Lim DH6, Lim HY1, Lee SJ1, Park SH1.
    View PubMed
  • Oncotarget. 2017 Feb 14;8(7):11094-11104. doi: 10.18632/oncotarget.14362. Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer Kim JH11, Lee SH2, Choi S2, Kim U3, Yeo IS4, Kim SH2, Oh MJ3, Moon H3, Lee J3, Jeong S3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Min YW5, Lee H5, Lee JH5, Rhee PL5, Kim JJ5, Lee SJ5, Kim ST5, Lee J5, Park SH5, Park JO5, Park YS5, Lim HY5, Kang WK5, An HJ3, Kim JH4.
    View PubMed
  • J Cancer. 2017 Feb 25;8(5):730-736. doi: 10.7150/jca.17887. eCollection 2017. An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients Lee JY11, Hong M2, Lee J3, Lee S3, Kim KM2, Park C4, Lim HY3.
    View PubMed
  • Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700. The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors Lim SH11, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.
    View PubMed
  • Transl Oncol. 2016 Oct;9(5):466-471. doi: 10.1016/j.tranon.2016.08.009. Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma Cho J11, Lee J1, Kim J1, Kim ST1, Lee S1, Kim SY1, Ha SY2, Park CK3, Lim HY4.
    View PubMed
  • Hepatology. 2016 Sep;64(3):774-84. doi: 10.1002/hep.28600. Epub 2016 May 17. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma Cheng AL11, Thongprasert S2, Lim HY3, Sukeepaisarnjaroen W4, Yang TS5, Wu CC6, Chao Y7, Chan SL8, Kudo M9, Ikeda M10, Kang YK11, Pan H12, Numata K13, Han G14, Balsara B15, Zhang Y15, Rodriguez AM16, Zhang Y15, Wang Y15, Poon RT17.
    View PubMed
  • BMC Urol. 2016 Aug 2;16(1):46. doi: 10.1186/s12894-016-0163-5. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma Kim MJ11, Park SH2, Lee JL3, Lee SH4, Lee SJ5, Lim HY5.
    View PubMed
  • Oncotarget. 2016 Jul 12;7(28):43492-43503. doi: 10.18632/oncotarget.9523. MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis Lee JY11, Lee I2, Chang WJ3, Ahn SM4,5, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Cho JH1, Kim SY1, Kim KM4,5, Lee S1, Kim ST1, Park SH1, Lee J1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • J Cancer Res Clin Oncol. 2016 Jun;142(6):1231-7. doi: 10.1007/s00432-016-2143-2. Epub 2016 Mar 16. Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin) Kim ST11, Ahn S2, Lee J1, Lee SJ1, Park SH1, Park YS1, Lim HY1, Kang WK1, Kim KM2, Park JO3.
    View PubMed
  • J Cancer. 2016 May 25;7(9):1044-8. doi: 10.7150/jca.14815. eCollection 2016. Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era Kim ST11, Lee SJ1, Park SH1, Park JO1, Lim HY1, Kang WK1, Lee J1, Park YS1.
    View PubMed
  • Cancer Res Treat. 2016 Apr;48(2):553-60. doi: 10.4143/crt.2015.155. Epub 2015 Aug 10. A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology Yi JH11, Kang JH2, Hwang IG3, Ahn HK4, Baek HJ5, Lee SI5, Lim DH5, Won YW6, Ji JH7, Kim HS8, Rha SY8, Oh SY9, Lee KE10, Lim T11, Maeng CH12, Kim MJ13, Kim ST13, Lee J13, Park JO13, Park YS13, Lim HY13, Kang WK13, Park SH13.
    View PubMed
  • Oncotarget. 2016 Apr 12;7(15):19610-9. doi: 10.18632/oncotarget.7526. Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment Song HN11,2, Lee C3,4, Kim ST1, Kim SY1, Kim NK3, Jang J1, Kang M1, Jang H1, Ahn S5, Kim SH5, Park Y6, Cho YB6, Heo JW6, Lee WY6, Park JO1, Lim HY1, Kang WK1, Park YS1, Park WY3,7,4, Lee J1, Kim HC6.
    View PubMed
  • Oncotarget. 2016 Apr 26;7(17):24088-96. doi: 10.18632/oncotarget.8175. Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer Kim ST11, Lee J1, Lee SJ1, Park SH1, Jung SH2, Park YS1, Lim HY1, Kang WK1, Park JO1.
    View PubMed
  • J Cancer. 2016 Feb 5;7(5):484-9. doi: 10.7150/jca.13711. eCollection 2016. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs Kim ST11, Ha SY2, Lee S1, Ahn S2, Lee J1, Park SH1, Park JO1, Lim HY1, Kang WK1, Kim KM2, Park YS1.
    View PubMed
  • BMC Cancer. 2016 Feb 18;16:120. doi: 10.1186/s12885-016-2141-4. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis Kim HS11,2, Heo JS3, Lee J4, Lee JY5, Lee MY6, Lim SH7, Lee WY8, Kim SH9, Park YA10, Cho YB11, Yun SH12, Kim ST13, Park JO14, Lim HY15, Choi YS16, Kwon WI17, Kim HC18, Park YS19.
    View PubMed
  • Clin Genitourin Cancer. 2016 Feb;14(1):76-81. doi: 10.1016/j.clgc.2015.09.008. Epub 2015 Sep 25. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma Kim YS11, Lee SI2, Park SH3, Park S3, Hwang IG4, Lee SC5, Sun JM3, Lee J3, Lim HY3.
    View PubMed
  • Tumori. 2016 Jan-Feb;102(1):114-21. doi: 10.5301/tj.5000439. Epub 2015 Oct 7. Clinical significance of mucinous rectal adenocarcinoma following preoperative chemoradiotherapy and curative surgery Kim TG11, Park W2, Choi DH2, Park HC2, Kim SH3, Cho YB4, Yun SH4, Kim HC4, Lee WY4, Lee J5, Park JO5, Park YS5, Lim HY5, Kang WK5, Chun HK6.
    View PubMed
  • Ann Oncol. 2015 Dec;26(12):2457-63. doi: 10.1093/annonc/mdv388. Epub 2015 Sep 18. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma Kang YK11, Yau T2, Park JW3, Lim HY4, Lee TY5, Obi S6, Chan SL7, Qin S8, Kim RD9, Casey M10, Chen C11, Bhattacharyya H11, Williams JA12, Valota O13, Chakrabarti D10, Kudo M14.
    View PubMed
  • Oncotarget. 2015 Nov 17;6(36):39028-35. doi: 10.18632/oncotarget.5494. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line Lee SJ11, Li GG2, Kim ST1, Hong ME3, Jang J1, Yoon N3, Ahn SM3, Murphy D2, Christiansen J2, Wei G2, Hornby Z2, Lee DW4, Park JO1,5, Park YS1, Lim HY1, Hong SN6, Kim SH3, Kang WK1, Park K1, Park WY7, Kim KM3,5, Lee J1.
    View PubMed
  • Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients Kim ST11, Lee WS2, Lanman RB3, Mortimer S3, Zill OA3, Kim KM4,5, Jang KT5, Kim SH5, Park SH1, Park JO1,4, Park YS1, Lim HY1, Eltoukhy H3, Kang WK1, Lee WY6, Kim HC6, Park K1,4, Lee J1,4, Talasaz A3.
    View PubMed
  • Br J Cancer. 2015 Nov 17;113(10):1421-6. doi: 10.1038/bjc.2015.371. Epub 2015 Oct 27. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer Lim SH11, Kim TW2, Hong YS2, Han SW3, Lee KH3, Kang HJ4, Hwang IG5, Lee JY1, Kim HS1, Kim ST1, Lee J1, Park JO1, Park SH1, Park YS1, Lim HY1, Jung SH6,7, Kang WK1.
    View PubMed
  • Oncotarget. 2015 Nov 24;6(37):40026-35. doi: 10.18632/oncotarget.5432. PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA Kim ST11, Lira M2, Deng S2, Lee S1, Park YS1, Lim HY1, Kang WK1, Mao M3, Heo JS4, Kwon W4, Jang KT5, Lee J1,6, Park JO1,6.
    View PubMed
  • Int J Biol Markers. 2015 Nov 11;30(4):e382-6. doi: 10.5301/jbm.5000151. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer Lee SJ11, Lee J1, Kim ST1, Park SH1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • Radiother Oncol. 2015 Oct;117(1):171-7. doi: 10.1016/j.radonc.2015.08.009. Epub 2015 Aug 20. Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial Yu JI11, Lim do H2, Ahn YC1, Lee J3, Kang WK3, Park SH3, Park JO3, Park YS3, Lim HY3, Kim ST3, Kim S4, Sohn TS4, Choi MG4, Bae JM4, Nam H5.
    View PubMed
  • BMC Cancer. 2015 Oct 20;15:747. doi: 10.1186/s12885-015-1759-y. Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan Kim ST1, Ahn TJ, Lee E, Do IG, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim SH, Lee J, Kim HC
    View PubMed
  • J Clin Oncol. 2015 Oct 1;33(28):3130-6. doi: 10.1200/JCO.2014.58.3930. Epub 2015 Jan 5. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses Park SH11, Sohn TS1, Lee J1, Lim DH1, Hong ME1, Kim KM1, Sohn I1, Jung SH1, Choi MG1, Lee JH1, Bae JM1, Kim S1, Kim ST1, Park JO1, Park YS1, Lim HY1, Kang WK2.
    View PubMed
  • J Hepatol. 2015 Oct;63(4):896-904. doi: 10.1016/j.jhep.2015.06.001. Epub 2015 Jun 10. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study Cheng AL11, Kang YK2, He AR3, Lim HY4, Ryoo BY2, Hung CH5, Sheen IS6, Izumi N7, Austin T8, Wang Q9, Greenberg J9, Shiratori S9, Beckman RA10, Kudo M11; Investigators’ Study Group.
    View PubMed
  • Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis Kim ST11, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.
    View PubMed
  • Mol Ther. 2015 Sep;23(9):1532-40. doi: 10.1038/mt.2015.109. Epub 2015 Jun 15. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer Park SH11, Breitbach CJ2, Lee J1, Park JO1, Lim HY1, Kang WK1, Moon A2,3, Mun JH4, Sommermann EM4, Maruri Avidal L4, Patt R5, Pelusio A2, Burke J2, Hwang TH4,6, Kirn D2, Park YS1.
    View PubMed
  • Oncotarget. 2015 Sep 22;6(28):25619-30. doi: 10.18632/oncotarget.4627. Patient-derived cell models as preclinical tools for genome-directed targeted therapy Lee JY11, Kim SY1, Park C1, Kim NK2, Jang J1, Park K2, Yi JH3, Hong M4,5, Ahn T2, Rath O6, Schueler J6, Kim ST1, Do IG5, Lee S1, Park SH1, Ji YI7, Kim D7, Park JO1,4, Park YS1, Kang WK1, Kim KM4,5, Park WY2,7, Lim HY1, Lee J1,4.
    View PubMed
  • Oncotarget. 2015 Sep 29;6(29):28211-22. doi: 10.18632/oncotarget.4721. Gastrointestinal malignancies harbor actionable MET exon 14 deletions Lee J11,2, Ou SH3, Lee JM4, Kim HC5, Hong M6, Kim SY1, Jang J1, Ahn S6, Kang SY6, Lee S1, Kim ST1, Kim B4, Choi J4, Kim KA4, Lee J1, Park C1,6, Park SH1, Park JO1,2, Lim HY1, Kang WK1, Park K1,2, Park YS1, Kim KM2,6.
    View PubMed
  • Oncotarget. 2015 Sep 15;6(27):24320-32. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening Lee J11, Kim HC2, Hong JY3, Wang K4, Kim SY1, Jang J1, Kim ST1, Park JO1, Lim HY1, Kang WK1, Park YS1, Lee J1, Lee WY2, Park YA2, Huh JW2, Yun SH2, Do IG5, Kim SH5, Balasubramanian S4, Stephens PJ4, Ross JS4,6, Li GG7, Hornby Z7, Ali SM4, Miller VA4, Kim KM5,8, Ou SH9.
    View PubMed
  • Cancer Chemother Pharmacol. 2015 Aug;76(2):257-67. doi: 10.1007/s00280-015-2787-7. Epub 2015 Jun 3. Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma Kim MN11, Ro SW, Kim do Y, Kim da Y, Cho KJ, Park JH, Lim HY, Han KH.
    View PubMed
  • Transl Oncol. 2015 Aug;8(4):288-94. doi: 10.1016/j.tranon.2015.06.001. Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer Kim ST11, Jang HL2, Lee J1, Park SH1, Park YS1, Lim HY1, Choi MG3, Bae JM3, Sohn TS3, Noh JH3, Kim S3, Kim KM4, Kang WK1, Park JO5.
    View PubMed
  • Cancer Res Treat. 2015 Jul;47(3):343-61. doi: 10.4143/crt.2014.308. Epub 2015 May 18. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review Park JO11, Oh DY2, Hsu C3, Chen JS4, Chen LT5, Orlando M6, Kim JS7, Lim HY1.
    View PubMed
  • BMC Cancer. 2015 Jul 21;15:530. doi: 10.1186/s12885-015-1552-y. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer Kim ST11, Jang KT2, Lee SJ3, Jang HL4, Lee J5, Park SH6, Park YS7, Lim HY8, Kang WK9, Park JO10.
    View PubMed
  • Radiology. 2015 Jul;276(1):274-85. doi: 10.1148/radiol.15141215. Epub 2015 Feb 25. Aggressive Intrasegmental Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation: Risk Factors and Clinical Significance Kang TW11, Lim HK1, Lee MW1, Kim YS1, Rhim H1, Lee WJ1, Gwak GY1, Paik YH1, Lim HY1, Kim MJ1.
    View PubMed
  • J Hepatol. 2015 May;62(5):1112-21. doi: 10.1016/j.jhep.2014.12.009. Epub 2014 Dec 13. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors Sohn W11, Paik YH2, Cho JY1, Lim HY1, Ahn JM1, Sinn DH1, Gwak GY1, Choi MS1, Lee JH1, Koh KC1, Paik SW1, Yoo BC1.
    View PubMed
  • Korean J Radiol. 2015 May-Jun;16(3):465-522. doi: 10.3348/kjr.2015.16.3.465. Epub 2015 May 13. 2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma Korean Liver Cancer Study Group (KLCSG); National Cancer Center1, Korea (NCC).
    View PubMed
  • Jpn J Clin Oncol. 2015 Mar;45(3):256-60. doi: 10.1093/jjco/hyu210. Epub 2015 Jan 26. Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC) Ji JH11, Song HN2, Kim RB3, Oh SY4, Lim HY5, Park JO5, Park SH5, Kim MJ5, Lee SI6, Ryou SH6, Hwang IG7, Jang JS7, Kim HJ8, Choi JY9, Kang JH10.
    View PubMed
  • Transl Oncol. 2015 Feb;8(1):40-6. doi: 10.1016/j.tranon.2014.12.003. Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer Kim ST11, Jang KT2, Lee J1, Jang HM3, Choi HJ4, Jang HL1, Park SH1, Park YS1, Lim HY1, Kang WK1, Park JO5.
    View PubMed
  • Cancer Res Treat. 2015 Jan;47(1):72-7. doi: 10.4143/crt.2013.172. Epub 2014 Aug 21. Changes in the Mean Corpuscular Volume after Capecitabine Treatment are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer Jung HA11, Kim HJ2, Maeng CH3, Park SH1, Lee J1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • BMC Cancer. 2014 Dec 3;14:906. doi: 10.1186/1471-2407-14-906. Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function Ha SH1, Park JH, Jang HR, Huh W, Lim HY, Kim YG, Kim DJ, Oh HY, Lee JE1.
    View PubMed
  • Sci Rep.?2014 Dec 23;4:7592. doi: 10.1038/srep07592. Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer Yi JH11,?Do IG2,?Jang J3,?Kim ST3,?Kim KM4,?Park SH3,?Park JO3,?Park YS3,?Lim HY3,?Kang WK3,?Lee J3.
    View PubMed
  • Clin Cancer Res.?2014 Dec 1;20(23):5976-85. doi: 10.1158/1078-0432.CCR-13-3445. Epub 2014 Oct 7. A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma Lim HY11,?Heo J2,?Choi HJ3,?Lin CY4,?Yoon JH5,?Hsu C6,?Rau KM7,?Poon RT8,?Yeo W9,?Park JW10,?Tay MH11,?Hsieh WS12,?Kappeler C13,?Rajagopalan P14,Krissel H13,?Jeffers M14,?Yen CJ15,?Tak WY16.
    View PubMed
  • Eur J Cancer. 2014 Nov;50(16):2822-30. doi: 10.1016/j.ejca.2014.08.005. Epub 2014 Sep 15. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study Kim ST11, Kang JH2, Lee J1, Park SH1, Park JO1, Park YS1, Lim HY1, Hwang IG3, Lee SC4, Park KW5, Lee HR6, Kang WK7.
    View PubMed
  • BMC Cancer. 2014 Nov 26;14:883. doi: 10.1186/1471-2407-14-883. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial Kim ST1, Hong YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Lee JW, Jo SJ, Park YS1.
    View PubMed
  • Mol Cancer Ther. 2014 Nov;13(11):2527-36. doi: 10.1158/1535-7163.MCT-14-0255. Epub 2014 Sep 23. Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification Kim ST11, Jang HL2, Lee SJ1, Lee J1, Choi YL3, Kim KM3, Cho J4, Park SH1, Park YS1, Lim HY1, Yashiro M5, Kang WK1, Park JO6.
    View PubMed
  • Anticancer Res. 2014 Nov;34(11):6585-91. Adjuvant Chemoradiation with 5-Fluorouracil/Leucovorin versus S-1 in Gastric Cancer Patients Following D2 Lymph Node Dissection Surgery: A Feasibility Study Lee SJ11, Sohn TS2, Lee J1, Park SH1, Park JO1, Lim DH3, Park YS1, Lim HY1, Choi MG4, Lee JH4, Bae JM4, Kim S4, Kang WK5.
    View PubMed
  • Cancer Chemother Pharmacol. 2014 Nov;74(5):1005-13. doi: 10.1007/s00280-014-2579-5. Epub 2014 Sep 6. Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program Lee JL11, Park SH, Koh SJ, Lee SH, Kim YJ, Choi YJ, Lee J, Lim HY.
    View PubMed
  • Med Oncol. 2014 Jul;31(7):23. doi: 10.1007/s12032-014-0023-7. Epub 2014 Jun 10. Prognostic and predictive value of metabolic tumor volume on F-18-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib Choi MK11, Choi JY, Lee J, Heo JS, Choi SH, Choi DW, Lee KT, Lee JK, Lee KH, Park JO, Park YS, Lim HY.
    View PubMed
  • JAMA. 2014 Jul 2;312(1):57-67. doi: 10.1001/jama.2014.7189. Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Trial Zhu AX11, Kudo M2, Assenat E3, Cattan S4, Kang YK5, Lim HY6, Poon RT7, Blanc JF8, Vogel A9, Chen CL10, Dorval E11, Peck-Radosavljevic M12, Santoro A13, Daniele B14, Furuse J15, Jappe A16, Perraud K16, Anak O16, Sellami DB17, Chen LT18.
    View PubMed
  • Invest New Drugs. 2014 Jun;32(3):535-41. doi: 10.1007/s10637-014-0065-x. Epub 2014 Jan 28. Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab Lee J11, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK.
    View PubMed
  • Br J Cancer. 2014 Jun 10;110(12):2821-8. doi: 10.1038/bjc.2014.244. Epub 2014 May 13. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial Escudier B11, Michaelson MD2, Motzer RJ3, Hutson TE4, Clark JI5, Lim HY6, Porfiri E7, Zalewski P8, Kannourakis G9, Staehler M10, Tarazi J11, Rosbrook B11, Cisar L12, Hariharan S12, Kim S11, Rini BI13.
    View PubMed
  • Cancer Res Treat. 2014 Apr;46(2):141-7. doi: 10.4143/crt.2014.46.2.141. Epub 2014 Apr 22. Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee Kwon KA11, Oh SY2, Kim HY3, Kim HS4, Lee HY1, Kim TM5, Lim HY6, Lee NR7, Lee HJ8, Hong SH9, Rha SY4.
    View PubMed
  • Eur J Cancer. 2014 Mar;50(4):746-52. doi: 10.1016/j.ejca.2013.11.029. Epub 2013 Dec 11. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency Kim KH11, Kim HY2, Kim HR3, Sun JM4, Lim HY4, Lee HJ5, Lee S6, Bae WK7, Rha SY8; Korean Cancer Study Group; Genitourinary & Gynecology Cancer Committee.
    View PubMed
  • Chemotherapy. 2014;60(2):73-80. doi: 10.1159/000368071. Epub 2014 Nov 29. Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer Jung HA11, Sun JM, Park SH, Kwon GY, Lim HY.
    View PubMed
  • J Clin Oncol. 2014 Mar 10;32(8):760-7. doi: 10.1200/JCO.2013.50.3961. Epub 2013 Dec 2. Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma Hutson TE11, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ.
    View PubMed
  • PLoS One. 2014 Mar 5;9(3):e90133. doi: 10.1371/journal.pone.0090133. eCollection 2014. Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery Lee J11, Sohn I2, Do IG3, Kim KM4, Park SH1, Park JO1, Park YS1, Lim HY1, Sohn TS5, Bae JM5, Choi MG5, Lim DH6, Min BH7, Lee JH7, Rhee PL7, Kim JJ7, Choi DI8, Tan IB9, Das K10, Tan P11, Jung SH2, Kang WK1, Kim S5.
    View PubMed
  • Liver Int. 2014 Feb;34(2):174-83. doi: 10.1111/liv.12314. Epub 2013 Nov 20. Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel Cheng AL11, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Park JW.
    View PubMed
  • Int J Colorectal Dis. 2014 Feb;29(2):193-200. doi: 10.1007/s00384-013-1797-3. Epub 2013 Dec 10. Factors associated with lateral pelvic recurrence after curative resection following neoadjuvant chemoradiotherapy in rectal cancer patients Kim TG11, Park W, Choi DH, Park HC, Kim SH, Cho YB, Yun SH, Kim HC, Lee WY, Lee J, Park JO, Park YS, Lim HY, Kang WK, Chun HK.
    View PubMed
  • Cancer Chemother Pharmacol. 2014 Jan;73(1):125-30. doi: 10.1007/s00280-013-2328-1. Epub 2013 Oct 27. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients Hong JY11, Nam EM, Lee J, Park JO, Lee SC, Song SY, Choi SH, Heo JS, Park SH, Lim HY, Kang WK, Park YS.
    View PubMed
  • BMC Med Genomics.?2014 Jan 9;7:2. doi: 10.1186/1755-8794-7-2. Whole-genome sequencing of matched primary and metastatic hepatocellular carcinomas Ouyang L1,?Lee J,?Park CK,?Mao M,?Shi Y,?Gong Z,?Zheng H,?Li Y,?Zhao Y,?Wang G,?Fu H,?Kim J1,?Lim HY.
    View PubMed
  • Ann Surg Oncol.?2013 Nov;20(12):3747-53. doi: 10.1245/s10434-013-3070-y. Epub 2013 Jun 26. Prediction of Disease-free Survival in Hepatocellular Carcinoma by Gene Expression Profiling Lim HY11,?Sohn I,?Deng S,?Lee J,?Jung SH,?Mao M,?Xu J,?Wang K,?Shi S,?Joh JW,?Choi YL,?Park CK.
    View PubMed
  • Anticancer Res.?2013 Nov;33(11):5179-86. A Survey of c-MET Expression and Amplification in 287 Patients with Hepatocellular Carcinoma Lee SJ11,?Lee J,?Sohn I,?Mao M,?Kai W,?Park CK,?Lim HY.
    View PubMed
  • Eur J Cancer. 2013 Nov;49(16):3412-9. doi: 10.1016/j.ejca.2013.05.028. Epub 2013 Jun 25. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study Bruix J11, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L.
    View PubMed
  • Anticancer Res.?2013 Oct;33(10):4619-26. Effects of Single Nucleotide Polymorphisms on Treatment Outcomes and Toxicity in Patients Treated with Sunitinib Maeng CH11,?Yi JH,?Lee J,?Hong JY,?Choi MK,?Jung HA,?Park JO,?Park SH,?Park YS,?Kang WK,?Lim HY.
    View PubMed
  • J Clin Oncol. 2013 Oct 1;31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. Epub 2013 Aug 26. Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study Llovet JM11, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW.
    View PubMed
  • J Clin Oncol. 2013 Oct 1;31(28):3501-8. doi: 10.1200/JCO.2012.44.5643. Epub 2013 Aug 26. Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia Qin S11, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y.
    View PubMed
  • Onkologie. 2013;36(7-8):421-6. doi: 10.1159/000349957. Epub 2013 Jun 22. 5-Fluorouracil, Mitomycin-C, and Polysaccharide-K versus Uracil-Ftorafur Polysaccharide-K as Adjuvant Chemoimmunotherapy for Patients with Locally Advanced Gastric Cancer with Curative Resection Ahn MS11, Kang SY, Lee HW, Jeong SH, Park JS, Lee KJ, Cho YK, Han SU, Lee SY, Lim HY, Choi JH.
    View PubMed
  • Liver Int.?2013 Jul;33(6):950-7. doi: 10.1111/liv.12168. Epub 2013 Apr 21. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma Cho JY11,?Paik YH,?Lim HY,?Kim YG,?Lim HK,?Min YW,?Gwak GY,?Choi MS,?Lee JH,?Koh KC,?Paik SW,?Yoo BC.
    View PubMed
  • Yonsei Med J.?2013 Jul;54(4):883-7. doi: 10.3349/ymj.2013.54.4.883. PIK3CA Mutations in Hepatocellular Carcinoma in Korea Kim H11,?Park CK,?Lee SJ,?Rha SY,?Park KH,?Lim HY.
    View PubMed
  • Ann Oncol. 2013 Jun;24(6):1567-73. doi: 10.1093/annonc/mdt002. Epub 2013 Feb 13. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma Roy AC11, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A.
    View PubMed
  • Ann Oncol. 2013 Apr;24(4):1026-31. doi: 10.1093/annonc/mds582. Epub 2012 Nov 23. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma Koh Y11, Lim HY, Ahn JH, Lee JL, Rha SY, Kim YJ, Kim TM, Lee SH.
    View PubMed
  • Nat Med. 2013 Mar;19(3):329-36. doi: 10.1038/nm.3089. Epub 2013 Feb 10. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer Heo J11, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kirn DH.
    View PubMed
  • Liver Int. 2013 Mar;33(3):327-37. doi: 10.1111/liv.12083. Epub 2013 Jan 18. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC) Park JW11, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Cheng AL.
    View PubMed
  • Invest New Drugs. 2012 Oct;30(5):1984-90. doi: 10.1007/s10637-011-9757-7. Epub 2011 Oct 20. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum Lee JL11, Ahn JH, Park SH, Lim HY, Kwon JH, Ahn S, Song C, Hong JH, Kim CS, Ahn H.
    View PubMed
  • Invest New Drugs.?2012 Aug;30(4):1768-72. doi: 10.1007/s10637-011-9707-4. Epub 2011 Jul 1. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma Ahn HK11,?Lee S,?Sun JM,?Lee J,?Park SH,?Park JO,?Park YS,?Kang WK,?Lim HY.
    View PubMed
  • Invest New Drugs.?2012 Aug;30(4):1540-7. doi: 10.1007/s10637-011-9706-5. Epub 2011 Jun 22. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma Lee SJ11,?Lee J,?Park SH,?Park JO,?Park YS,?Kang WK,?Lee J,?Yim DS,?Lim HY.
    View PubMed
  • Ann Oncol. 2012 Aug;23(8):2108-14. doi: 10.1093/annonc/mdr586. Epub 2012 Jan 6. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma Lee JL11, Ahn JH, Lim HY, Park SH, Lee SH, Kim TM, Lee DH, Cho YM, Song C, Hong JH, Kim CS, Ahn H.
    View PubMed
  • BMC?Cancer.?2012 May 22;12:187. doi: 10.1186/1471-2407-12-187. ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy Sun JM11,?Sung JY,?Park SH,?Kwon GY,?Jeong BC,?Seo SI,?Jeon SS,?Lee HM,?Jo J,?Choi HY,?Lim HY.
    View PubMed
  • Clin Cancer Res. 2012 Apr 1;18(7):2090-8. doi: 10.1158/1078-0432.CCR-11-1991. Epub 2012 Jan 11. Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma Finn RS11, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I, Baudelet C, Manekas D, Park JW.
    View PubMed
  • Asian Pac J Cancer Prev. 2012;13(4):1419-24. Complementary and Alternative Medicine Use among Cancer Patients at the End of Life: Korean National Study Choi JY11, Chang YJ, Hong YS, Heo DS, Kim S, Lee JL, Choi JS, Kang KM, Kim SY, Jeong HS, Lee CG, Choi YS, Lim HY, Yun YH.
    View PubMed
  • Int J Cancer. 2012 Feb 15;130(4):948-58. doi: 10.1002/ijc.26081. Epub 2011 May 25. Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection Kang SY11, Han JH, Ahn MS, Lee HW, Jeong SH, Park JS, Cho YK, Han SU, Kim YB, Kim JH, Sheen SS, Lim HY, Choi JH.
    View PubMed
  • Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
    View PubMed
  • Eur J Cancer.?2012 Jan;48(2):196-201. doi: 10.1016/j.ejca.2011.11.017. Epub 2011 Dec 14. A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study Yi JH11,?Thongprasert S,?Lee J,?Doval DC,?Park SH,?Park JO,?Park YS,?Kang WK,?Lim HY.
    View PubMed
  • Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Rini BI11, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ.
    View PubMed
  • J Korean Med Sci.?2011 Dec;26(12):1563-8. doi: 10.3346/jkms.2011.26.12.1563. Epub 2011 Nov 29. Novel EGFR-TK Inhibitor EKB-569 Inhibits Hepatocellular Carcinoma Cell Proliferation by AKT and MAPK Pathways Kim H11,?Lim HY.
    View PubMed
  • Cancer Chemother Pharmacol. 2011 Oct;68(4):935-44. doi: 10.1007/s00280-011-1558-3. Epub 2011 Feb 5. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients Hwang IG11, Jang JS, Do JH, Kang JH, Lee GW, Oh SY, Kwon HC, Jun HJ, Lim HY, Lee S, Chi KC, Lee SJ.
    View PubMed
  • Onkologie.?2011;34(8-9):416-20. doi: 10.1159/000331129. Epub 2011 Aug 23. Salvage Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin (TIP) in Relapsed or Cisplatin-Refractory Germ Cell Tumors Park S11,?Lee S,?Lee J,?Park SH,?Park JO,?Kang WK,?Park YS,?Lim HY.
    View PubMed
  • J Transl Med. 2011 Jul 25;9:120. doi: 10.1186/1479-5876-9-120. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib Harmon CS11, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, Lim HY, Kim JS, Lechuga MJ, Lanzalone S, Lin X, Faivre S.
    View PubMed
  • Clin Cancer Res. 2011 Jul 1;17(13):4504-12. doi: 10.1158/1078-0432.CCR-10-1708. Epub 2011 Apr 29. Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib Faivre S11, Zappa M, Vilgrain V, Boucher E, Douillard JY, Lim HY, Kim JS, Im SA, Kang YK, Bouattour M, Dokmak S, Dreyer C, Sablin MP, Serrate C, Cheng AL, Lanzalone S, Lin X, Lechuga MJ, Raymond E.
    View PubMed
  • Oncology.?2011;80(3-4):167-74. doi: 10.1159/000327591. Epub 2011 Jun 24. Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Retrospective Comparison with Previously Known Prognostic Models Baek KK11,?Kim JH,?Uhm JE,?Park SH,?Lee J,?Park JO,?Park YS,?Kang WK,?Lim HY.
    View PubMed
  • Invest New Drugs. 2011 Apr;29(2):366-73. doi: 10.1007/s10637-009-9363-0. Epub 2009 Dec 9. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer Kim C11, Lee JL, Ryu MH, Chang HM, Kim TW, Lim HY, Kang HJ, Park YS, Ryoo BY, Kang YK.
    View PubMed
  • Dig Dis Sci. 2011 Jan;56(1):131-8. doi: 10.1007/s10620-010-1280-8. Epub 2010 May 26. Bax Predicts Outcome in Gastric Cancer Patients Treated with 5-fluorouracil, Leucovorin, and Oxaliplatin Palliative Chemotherapy Jeong SH11, Han JH, Kim JH, Ahn MS, Hwang YH, Lee HW, Kang SY, Park JS, Choi JH, Lee KJ, Sheen SS, Lim HY.
    View PubMed
  • Chemotherapy.?2010;56(6):485-91. doi: 10.1159/000321033. Epub 2010 Nov 24. Treatment of Hemodialyzed Patients with Sunitinib in Renal Cell Carcinoma Park S11,?Lee J,?Park SH,?Park JO,?Kang WK,?Park YS,?Cho JH,?Lim HY.
    View PubMed
  • APMIS.?2010 Dec;118(12):941-8. doi: 10.1111/j.1600-0463.2010.02648.x. Epub 2010 Oct 25. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy Kim KH11,?Do IG,?Kim HS,?Chang MH,?Kim HS,?Jun HJ,?Uhm J,?Yi SY,?Lim do H,?Ji SH,?Park MJ,?Lee J,?Park SH,?Kwon GY,?Lim HY.
    View PubMed
  • Eur J Clin Pharmacol. 2010 Dec;66(12):1235-45. doi: 10.1007/s00228-010-0885-3. Epub 2010 Sep 9. Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration Ahn BJ11, Choi MK, Park YS, Lee J, Park SH, Park JO, Lim HY, Kang WK, Ko JW, Yim DS.
    View PubMed
  • BMC Cancer. 2010 Nov 10;10:620. doi: 10.1186/1471-2407-10-620. Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma Yeo W11, Chen PJ, Furuse J, Han KH, Hsu C, Lim HY, Moon H, Qin S, Yeoh EM, Ye SL.
    View PubMed
  • Liver Int. 2010 Nov;30(10):1427-38. doi: 10.1111/j.1478-3231.2010.02292.x. Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion Chen PJ11, Furuse J, Han KH, Hsu C, Lim HY, Moon H, Qin S, Ye SL, Yeoh EM, Yeo W.
    View PubMed
  • Support Care Cancer. 2010 Jun;18(6):699-706. doi: 10.1007/s00520-009-0668-5. Epub 2009 May 31. Impact of caregivers' unmet needs for supportive care on quality of terminal cancer care delivered and caregiver's workforce performance Park SM11, Kim YJ, Kim S, Choi JS, Lim HY, Choi YS, Hong YS, Kim SY, Heo DS, Kang KM, Jeong HS, Lee CG, Moon do H, Choi JY, Kong IS, Yun YH.
    View PubMed
  • Urol Oncol.?2010 Mar-Apr;28(2):157-63. doi: 10.1016/j.urolonc.2008.08.002. Epub 2008 Oct 31. Molecular biomarkers for advanced renal cell carcinoma: Implications for prognosis and therapy Kim HS11,?Kim WS,?Park SH,?Jung CW,?Choi HY,?Lee HM,?Jeon SS,?Ha H,?Hwang IG,?Lee S,?Lim HY.
    View PubMed
  • Cancer Chemother Pharmacol. 2010 Mar;65(4):641-7. doi: 10.1007/s00280-009-1069-7. Epub 2009 Aug 4. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial Jang JS11, Lim HY, Hwang IG, Song HS, Yoo N, Yoon S, Kim YH, Park E, Byun JH, Lee MA, Oh SJ, Lee KH, Kim BS, Oh SC, Kim SY, Lee SJ.
    View PubMed
  • Support Care Cancer. 2010 Feb;18(2):189-96. doi: 10.1007/s00520-009-0644-0. Epub 2009 Apr 28. The life-sustaining treatments among cancer patients at end of life and the caregiver's experience and perspectives Yun YH11, Lee MK, Chang YJ, You CH, Kim S, Choi JS, Lim HY, Lee CG, Choi YS, Hong YS, Kim SY, Heo DS, Jeong HS.
    View PubMed
  • World J Gastroenterol. 2009 Oct 28;15(40):5086-90. Gastric leptomeningeal carcinomatosis: Multi-center retrospective analysis of 54 cases Oh SY11, Lee SJ, Lee J, Lee S, Kim SH, Kwon HC, Lee GW, Kang JH, Hwang IG, Jang JS, Lim HY, Park YS, Kang WK, Kim HJ.
    View PubMed
  • Lancet Oncol. 2009 Aug;10(8):794-800. doi: 10.1016/S1470-2045(09)70171-8. Epub 2009 Jul 6. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study Faivre S11, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, Harmon C, Ruiz-Garcia A, Lechuga MJ, Cheng AL.
    View PubMed
  • Cancer Chemother Pharmacol. 2009 Jul;64(2):317-25. doi: 10.1007/s00280-008-0873-9. Epub 2008 Nov 26. Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study Lee KH11, Kim MK, Kim YH, Ryoo BY, Lim HY, Song HS, Kim HK, Lee MA, Im SA, Chang HM, Cho JY, Zang DY, Kim BS, Kim JS.
    View PubMed
  • Med Oncol.?2009;26(2):186-92. doi: 10.1007/s12032-008-9106-7. Epub 2008 Nov 6. Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract Hong JY11,?Choi MK,?Uhm JE,?Park MJ,?Lee J,?Park SH,?Park JO,?Kim WS,?Kang WK,?Lee HM,?Choi HY,?Lim H.
    View PubMed
  • Cancer Chemother Pharmacol.?2009 Apr;63(5):929-35. doi: 10.1007/s00280-008-0817-4. Epub 2008 Aug 23. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma Uhm JE11,?Park JO,?Lee J,?Park YS,?Park SH,?Yoo BC,?Paik SW,?Koh KC,?Kang WK,?Lim HY.
    View PubMed
  • Cancer Res Treat. 2009 Mar;41(1):12-8. doi: 10.4143/crt.2009.41.1.12. Epub 2009 Mar 31. Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer Lee KH11, Hyun MS, Kim HK, Jin HM, Yang J, Song HS, Do YR, Ryoo HM, Chung JS, Zang DY, Lim HY, Jin JY, Yim CY, Park HS, Kim JS, Sohn CH, Lee SN.
    View PubMed
  • Jpn J Clin Oncol. 2008 Oct;38(10):661-9. doi: 10.1093/jjco/hyn089. Epub 2008 Sep 4. Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology Jeong SH11, Lee HW, Han JH, Kang SY, Choi JH, Jung YM, Choi H, Oh YT, Park KJ, Hwang SC, Sheen SS, Oh YJ, Kim JH, Lim HY.
    View PubMed
  • Lung Cancer. 2008 Jan;59(1):95-104. Epub 2007 Sep 21. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer Lee HW11, Han JH, Kim JH, Lee MH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, Hwang SC, Sheen SS, Lim HY.
    View PubMed
  • Cancer?Chemother Pharmacol.?2007 Aug;60(3):321-8. Epub 2006 Dec 2. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer Hong YS11,?Lee J,?Lee SC,?Hwang IG,?Choi SH,?Heo JS,?Park JO,?Park YS,?Lim HY,?Kang WK.
    View PubMed
  • Clin Cancer Res. 2007 Jul 15;13(14):4146-53. Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy Kang SY11, Han JH, Lee KJ, Choi JH, Park JI, Kim HI, Lee HW, Jang JH, Park JS, Kim HC, Kang S, Oh YT, Chun M, Kim JH, Sheen SS, Lim HY.
    View PubMed
  • Acta Pharmacol Sin. 2007 Mar;28(3):367-74. Endothelial progenitor cell differentiation using cryopreserved, umbilical cord blood-derived mononuclear cells Jang JH11, Kim SK, Choi JE, Kim YJ, Lee HW, Kang SY, Park JS, Choi JH, Lim HY, Kim HC.
    View PubMed
  • Neoplasia.?2007 Jan;9(1):18-22. Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract Uhm JE11,?Lim HY,?Kim WS,?Choi HY,?Lee HM,?Park BB,?Park K,?Kang WK.
    View PubMed
  • Oncology. 2007;72(3-4):164-71. Epub 2007 Dec 20. Chemotherapy use and associated factors among cancer patients near the end of life Yun YH11, Kwak M, Park SM, Kim S, Choi JS, Lim HY, Lee CG, Choi YS, Hong YS, Kim SY, Heo DS.
    View PubMed